This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SkinMedica vs. SkinCeuticals Retinol: Which One is Worth Your Money? When youre dropping serious cash on medical-grade skincare, you want to know for sure that youre picking the right one. SkinMedica and. SkinCeuticals both have Retinol products that promise smoother skin, fewer breakouts, and anti-aging magic. But which one actually delivers the best results for your […] The post SkinMedica vs.
Twice-daily ruxolitinib cream 1.5% (Opzelura, Incyte) met all primary and key secondary endpoints in a Phase 3 trial of adults with prurigo nodularis (PN). The research was presented as a late-breaker at the 2025American Academy of Dermatology(AAD) Annual Meeting inOrlando, FL. The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% a topical JAK1/2 inhibitor in adult patients (18 years) with
Torqur AGs topical bimiralisib, a selective pan-PI3K/mTOR inhibitor, may help clear actinic keratosis (AK) lesions, according to interim Phase 2 results presented at the American Academy of Dermatology in Orlando, FL. Specifically, 60% of trial patients experienced full or partial AK lesion clearance. Overactivation of the phosphoinositide 3-kinase (PI3K)/mechanistic target of the rapamycin (mTOR) pathway may contribute to the development of AK.
Nck modulators are a new class oforal small molecules that inhibit Nck from binding to the T cell receptor (or TCR),blocking TCR activationto treat autoimmune diseases without causing immunosuppression.Christopher VanDeusen, PhD, Chief Scientific Officer of Artax Biopharma, explains how this new approach may help treat a panoply of dermatologic diseases.
April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.
April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.
I don’t get it. Would you buy a delicate designer dress that’s “dry clean” only and throw it in the washing machine? Of course not. You know that’s like throwing $1000 down the toilet. *shudders* Yet that’s exactly what you’re doing when you’re buying a retinol cream packaged in a jar. Here’s why: What Is […] The post Why You Shouldn’t Buy Retinol Products Packaged In Jars appeared first on Beautiful With Brains.
The ADORING 3 study demonstrated that tapinarof cream 1% maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.
In case you missed it, this week we had news about the achievements of female dermatologists for Womens History Month, Takedas initiative to improve clinical disparities in psoriasis research, previews of this weeks AAD Annual Meeting, and more.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content